Financhill
Back

Emergent BioSolutions 10K Form

Sell
35

EBS
Emergent BioSolutions

Last Price:
2.54
Seasonality Move:
-0.41%

7 Day Trial

ALL ACCESS PASS

$ 7

Receive EBS News And Ratings

See the #1 stock for the next 7 days that we like better than EBS

EBS Financial Statistics

Sales & Book Value

Annual Sales: $1.02B
Cash Flow: $20.7M
Price / Cash Flow: 0
Annual Sales: $12.44
Price / Book: 0.21

Profitability

EPS (TTM): -14.76000
Net Income (TTM): $-757.2M
Gross Margin: $317.6M
Return on Equity: -77.37%
Return on Assets: -31.52%

Emergent BioSolutions Earnings Forecast

Key Emergent BioSolutions Financial Ratios

  • The Gross Profit Margin over the past 22 years for EBS is 31.05%.
  • The Selling, General & Administrative Expenses for EBS have been equal to 36.01% of Gross Profit Margin.
  • The Research & Development expenses have been 10.89% of Revenue.
  • The Interest Expense is -11.56% of Operating Income.
  • The Net Earning history of EBS is -74.34% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 12 years.

Emergent BioSolutions Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Current Symbol: EBS
CUSIP: 29089Q
Website: emergentbiosolutions.com

Debt

Debt-to-Equity Ratio: 1.32
Current Ratio: 1.04
Quick Ratio: 0.46

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0.71

EBS Technical Analysis vs Fundamental Analysis

Sell
35
Emergent BioSolutions (EBS) is a Sell

Is Emergent BioSolutions a Buy or a Sell?